Skip to main content
CHE $532.88 -0.80%
CHE logo

CHE · Chemed Corp

Track CHE — free
$532.88 -4.29 (-0.80%) At close · Aug 14
Market Cap
$6.96B
Shares
13.07M
All earnings calls

Earnings call · FY2026 Q1

Chemed Corp Q1 FY2026 Earnings Call

Chemed Corp Q1 FY2026 Earnings Call

Concluded Apr 24, 2026 Audio replay
Apr 24, 2026 47:57 62 turns
Period
FY2026 Q1
Runtime
47:57
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Chemed reported Q1 2026 consolidated revenue of $657.5 million, up 1.6%, with VITAS admissions rising 6.9% and the company raising full-year guidance, while Roto-Rooter revenue declined 0.9% and adjusted EBITDA margin fell 218 basis points.

VITAS admissions and patient mix 30 VITAS regulatory and fraud concerns 15 Florida Medicare cap position 14 Roto-Rooter commercial and water restoration 13 Roto-Rooter franchise acquisitions 7 Roto-Rooter paid leads and marketing 6

Management tone

Confident

Net tone +62 · moderate hedging

Grounding quotes
  • “VTAS performance during the quarter exceeded even the high end of our expectations.”
  • “We are more confident than ever that VTAS has put the Florida cap issue of 2025 behind us and has returned to a normalized rate of growth.”
  • “We feel very positive that the initiatives we have discussed over the last few quarters are beginning to take hold.”
  • “We are happy with the performance of VTAS of the quarter and its prospects for the remainder of 2026 and beyond.”

Forward guidance

6 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $657.51M +1.6% YoY
Diluted EPS $4.84 -0.4% YoY
Net income $66.30M -7.6% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • VITAS net revenue increased 3.1% to $420.0 million with admissions up 6.9% to 19,394
  • VITAS adjusted EBITDA excluding Medicare Cap rose 0.6% to $70.8 million
  • No Medicare Cap billing limitation recorded for Florida combined program and none anticipated for 2026 fiscal period, with over $32.5 million added to Florida cap cushion in the quarter
  • Roto-Rooter residential plumbing and residential sewer/drain revenue both increased for the first time since Q4 2022
  • Paid leads at Roto-Rooter increased 18.7% versus prior-year quarter
  • Company repurchased 500,000 shares in the quarter and raised full-year guidance

Risks & pressure points

  • GAAP diluted EPS decreased 0.4% to $4.84
  • VITAS adjusted EBITDA margin excluding Medicare Cap declined 41 basis points to 16.8%, and gross margin excluding Medicare Cap fell 71 basis points to 22.9%
  • Roto-Rooter revenue declined 0.9% to $237.5 million, with adjusted EBITDA down 9.6% to $53.5 million
  • Roto-Rooter adjusted EBITDA margin declined 218 basis points to 22.5%
  • Weather-related service disruptions at 24 branches over five days caused an estimated $3–4 million revenue loss
  • Acuity mix shift negatively impacted VITAS revenue growth by 120 basis points, and high-acuity days-of-care fell 28 basis points

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Apr 23, 2026.

Metric Guided
ADC growth
2026
4.5% – 5.5%
Revenue growth, excluding the impact of the Medicare Cap
2026
6.5% – 7.5%
Roto-Rooter revenue growth
fiscal 2026
3% – 3.5%
EBITDA margin, excluding the impact of the Medicare Cap
2026
18% – 18.5%
Roto-Rooter adjusted EBITDA margin
fiscal 2026
21.5% – 22.5%
Adjusted earnings per diluted share
2026
$24.00 – $24.75

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Segment Vitas$420.02M +3.1% YoY
Segment Roto Rooter$237.50M -0.9% YoY

Capital returned

Buybacks
$190.04M
Shares repurchased
500,000
Dividend / share
$0.60
Full-screen source Call document